Increased expression of SSEA-4 on TKI-resistant non–small cell lung cancer with EGFR-T790M mutation
Proceedings of the National Academy of Sciences · 30.01.2024 · 121 (5)
DOI: 10.1073/pnas.2313397121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 22.01.2024. Verfasst von Nai-Yu Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Stage-Specific Embryonic Antigens. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AS | Genomics Research Center, Academia Sinica (GRC).
Abstract (Originalsprache)
Non–small cell lung cancer (NSCLC), a major life-threatening disease accounting for 85% of all lung cancer cases, has been treated with tyrosine kinase inhibitors (TKIs), but often resulted in drug resistance, and approximately 60% of TKI-resistant cases are due to acquired secondary (epithelial growth factor receptor) EGFR-T790M mutation. To identify alternative targets for TKI-resistant NSCLC with EGFR-T790M mutation, we found that the three globo-series glycosphingolipids are increasingly expressed on this type of NSCLC cell lines, and among them, the increase of stage-specific embryonic antigen-4 (SSEA-4) expression is the most significant. Compared to TKI-sensitive cell lines, SSEA-4 and the key enzyme β3GalT5 responsible for the synthesis of SSEA3 are more expressed in TKI-resistant NSCLC cell lines with EGFR-T790M mutation, and the expression levels strongly correlate with poor survival in patients with EGFR mutation. In addition, we demonstrated that a SSEA-4 targeted monoclonal antibody, especially the homogeneous glycoform with well-defined Fc glycan designed to improve effective functions, is highly effective against this subpopulation of NSCLC in cell-based and animal studies. These findings provide a direction for the prediction of tumor recurrence and treatment of TKI-resistant NSCLC with EGFR-T790M mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.
- Institute of Microbiology and Immunology, National Yang-Ming University, Taipei 11221, Taiwan.
- Institute of Biochemistry and Molecular Biology, China Medical University, Taichung 406040, Taiwan.
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan.
- Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037.
ORCID-Profile: Chi-Huey Wong
Förderung
- AS | Genomics Research Center, Academia Sinica (GRC)
Zitieren
APA
Chen, N. Y., Lin, C. W., Lai, T. Y., Wu, C. Y., Liao, P. C., Hsu, T. L., & Wong, C. H. (2024). Increased expression of SSEA-4 on TKI-resistant non–small cell lung cancer with EGFR-T790M mutation. Proceedings of the National Academy of Sciences, 121(5). https://doi.org/10.1073/pnas.2313397121
Vancouver
Chen NY, Lin CW, Lai TY, Wu CY, Liao PC, Hsu TL, et al. Increased expression of SSEA-4 on TKI-resistant non–small cell lung cancer with EGFR-T790M mutation. Proceedings of the National Academy of Sciences. 2024;121(5). doi:10.1073/pnas.2313397121
BibTeX
@article{Chen2024,
author = {Chen, Nai-Yu and Lin, Chih-Wei and Lai, Ting-Yen and Wu, Chung-Yi and Liao, Pei-Chi and Hsu, Tsui-Ling and Wong, Chi-Huey},
title = {Increased expression of SSEA-4 on TKI-resistant non–small cell lung cancer with EGFR-T790M mutation},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {5},
doi = {10.1073/pnas.2313397121}
}
EUVIMED